miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen’s areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research
Company profile
Ticker
VRDN
Exchange
Website
CEO
William Marshall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS LLC, SIGNAL GENETICS, INC.
SEC CIK
Corporate docs
Subsidiaries
Viridian Therapeutics Europe Limited • Viridian Securities Corporation ...
VRDN stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
16 Apr 24
S-8
Registration of securities for employees
28 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Entry into a Material Definitive Agreement
19 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
424B5
Prospectus supplement for primary offering
17 Jan 24
8-K
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
8 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
18 Dec 23
S-3ASR
Automatic shelf registration
30 Nov 23
Transcripts
VRDN
Earnings call transcript
2023 Q1
9 May 23
VRDN
Earnings call transcript
2022 Q4
8 Mar 23
VRDN
Earnings call transcript
2022 Q3
14 Nov 22
VRDN
Earnings call transcript
2022 Q2
15 Aug 22
VRDN
Earnings call transcript
2022 Q1
13 May 22
VRDN
Earnings call transcript
2021 Q4
11 Mar 22
VRDN
Earnings call transcript
2020 Q4
25 Mar 21
VRDN
Earnings call transcript
2020 Q2
5 Aug 20
VRDN
Earnings call transcript
2020 Q1
10 May 20
VRDN
Earnings call transcript
2019 Q4
11 Mar 20
Latest ownership filings
SC 13D/A
Fairmount Funds Management LLC
1 Apr 24
4
Change in insider ownership
1 Apr 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Paradigm Biocapital Advisors LP
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
3
Jennifer Tousignant
14 Feb 24
4
Jennifer Tousignant
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 111.60 mm | 111.60 mm | 111.60 mm | 111.60 mm | 111.60 mm | 111.60 mm |
Cash burn (monthly) | (no burn) | 19.38 mm | 17.07 mm | 19.34 mm | 12.99 mm | 15.02 mm |
Cash used (since last report) | n/a | 129.69 mm | 114.23 mm | 129.37 mm | 86.93 mm | 100.47 mm |
Cash remaining | n/a | -18.09 mm | -2.64 mm | -17.77 mm | 24.66 mm | 11.13 mm |
Runway (months of cash) | n/a | -0.9 | -0.2 | -0.9 | 1.9 | 0.7 |
Institutional ownership, Q3 2023
97.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 130 |
Opened positions | 14 |
Closed positions | 25 |
Increased positions | 55 |
Reduced positions | 36 |
13F shares | Current |
---|---|
Total value | 754.21 bn |
Total shares | 61.02 mm |
Total puts | 31.00 k |
Total calls | 7.50 k |
Total put/call ratio | 4.1 |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners III | 4.23 mm | $0.00 |
Paradigm Biocapital Advisors | 3.68 mm | $56.48 bn |
VR Adviser | 3.08 mm | $47.29 bn |
BLK Blackrock | 2.99 mm | $45.91 bn |
Deep Track Capital | 2.96 mm | $45.46 bn |
STT State Street | 2.94 mm | $45.13 bn |
Vanguard | 2.45 mm | $37.55 bn |
Biotechnology Value Fund L P | 2.30 mm | $0.00 |
Commodore Capital | 2.20 mm | $33.75 bn |
Ra Capital Management | 2.01 mm | $30.80 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Mar 24 | Fairmount Funds Management | Common Stock | Other | Acquire J | Yes | No | 0 | 5,859 | 0.00 | 1,845,813 |
28 Mar 24 | Fairmount Funds Management | Common Stock | Other | Dispose J | Yes | No | 0 | 5,859 | 0.00 | 0 |
28 Mar 24 | Fairmount Funds Management | Series A Non-Voting Convertible Preferred Stock Common Stock | Other | Acquire J | Yes | No | 0 | 21,999 | 0.00 | 133,191 |
28 Mar 24 | Fairmount Funds Management | Series A Non-Voting Convertible Preferred Stock Common Stock | Other | Dispose J | Yes | No | 0 | 21,999 | 0.00 | 0 |
5 Feb 24 | Thomas Ciulla | Stock Option Common Stock | Grant | Acquire A | No | No | 18.7 | 50,000 | 935.00 k | 50,000 |
22 Jan 24 | Fairmount Funds Management | Common Stock | Buy | Acquire P | Yes | No | 21 | 476,190 | 10.00 mm | 1,839,954 |
10 Nov 23 | Seth Harmon | Stock Option Common Stock | Grant | Acquire A | No | No | 13.76 | 270,000 | 3.72 mm | 270,000 |
News
B. Riley Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $25
21 Mar 24
Unveiling 4 Analyst Insights On Viridian Therapeutics
20 Mar 24
Needham Maintains Buy on Viridian Therapeutics, Maintains $30 Price Target
20 Mar 24
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $37 Price Target
29 Feb 24
Navigating 6 Analyst Ratings For Viridian Therapeutics
28 Feb 24
Press releases
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
VIRIDIAN SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
29 Mar 24
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 Mar 24
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
16 Feb 24